MedTrace Logo

Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes

NCT01486875 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1155

Last updated 2017-01-06

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to evaluate the incidence of serious adverse drug reactions when initiating insulin therapy with NovoMix® 30 in subjects with type 2 diabetes mellitus under normal clinical practice conditions in Sweden.

Conditions

Interventions

DRUG

biphasic insulin aspart 30

Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Min Age
18 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01486875 on ClinicalTrials.gov